Estrella Durá-Ferrandis

Estrella Durá-Ferrandis

Auto-generated profile, based on publicly available information

Estrella Durá-Ferrandis

Universitat de València

Research Focus & Metrics

Academic Career Length

57Years (1970-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2012 in Psychology & Health
Verified
Journal Article
Closed access
YAYolanda Andreu
Yolanda Andreu
MGMaría José Galdón
María José Galdón
EDEstrella Durá
Estrella Durá
PMPaula Martínez
Paula Martínez
SRSANDRA PEREZ RODRIGUEZ
SANDRA PEREZ RODRIGUEZ
SMSergio Murgui
Sergio Murgui
This longitudinal study was conducted among 102 women with non-metastasic breast cancer to identify the time evolution and prevalence of distress at specific times through diagnosis and treatment of disease: preliminary diagnosis, surgery, definitive diagnosis and chemotherapy. Additionally, the study aimed to examine the role of demographic, medical and psychosocial factors on distress. The results indicated that prevalence of distress was higher at initial diagnosis (25%) than the following time points (approximately 17%). The differences inter-individuals in the levels of distress were observed over the four assessments. No relation between distress and demographic and medical factors was found. However, psychosocial aspects were significant risk factors. Patterns of emotional suppression and specific coping responses like helplessness/hopelessness, anxious preoccupation, cognitive avoidance and fatalism were positively related to distress, whereas fighting spirit and perceived social support showed a protective role. Moreover, helplessness/hopelessness and anxious preoccupation jointly predicted 75% of cases and 98% non-cases of distress. Finally, a mediational model between emotional suppression and distress through helplessness/hopelessness was tested. Results support the necessity of routine distress screening all through the illness. Implications of data for psychosocial interventions with breast cancer patients are highlighted.

22 July 2016 in Cancer
Verified
Journal Article
Open access
PDF file
JMJeanne S. Mandelblatt
Jeanne S. Mandelblatt
JCJonathan D. Clapp
Jonathan D. Clapp
GLGheorghe Luta
Gheorghe Luta
LFLeigh Anne Faul
Leigh Anne Faul
MTMichelle D. Tallarico
Michelle D. Tallarico
CIClaudine Isaacs
Claudine Isaacs
BACKGROUND: The number of survivors of breast cancer aged ≥65 years (“older”) is growing, but to the authors' knowledge, little is known regarding the cognitive outcomes of these individuals.METHODS: A cohort of cognitively intact older survivors with nonmetastatic, invasive breast cancer was recruited from 78 sites from 2004 through 2011; approximately 83.7% of the survivors (1280 survivors) completed baseline assessments. Follow‐up data were collected at 6 months and annually for up to 7 years (median, 4.1 years). Cognitive function was self‐reported using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ‐C30); scores ranged from 0 to 100, with a higher score indicating better function. Group‐based trajectory modeling determined trajectories; women were assigned to a trajectory group based on the highest predicted probability of membership. Multinomial logistic regression evaluated the association between receipt of chemotherapy (with or without hormonal treatment) and trajectory group.RESULTS: Survivors were aged 65 to 91 years; approximately 41% received chemotherapy. There were 3 cognitive trajectories: “maintained high” (42.3% of survivors); “phase shift” (50.1% of survivors), with scores slightly below but parallel to maintained high; and “accelerated decline” (7.6% of survivors), with the lowest baseline scores and greatest decline (from 71.7 [standard deviation, 19.8] to 58.3 [standard deviation, 21.9]). The adjusted odds of being in the accelerated decline group (vs the maintained high group) were 2.1 times higher (95% confidence interval, 1.3‐3.5) for survivors who received chemotherapy (with or without hormonal therapy) versus those treated with hormonal therapy alone. Greater comorbidity and frailty also were found to be associated with accelerated decline.CONCLUSIONS: Trajectory group analysis demonstrated that the majority of older survivors maintained good long‐term self‐reported cognitive function, and that only a small subset who were exposed to chemotherapy manifested accelerated cognitive decline. Future research is needed to determine factors that place some older survivors at risk of experiencing cognitive decline. Cancer 2016;122:3555–3563. © 2016 American Cancer Society

20 February 2017 in Psycho-Oncology
Verified
Journal Article
Closed access
PDF file
EDEstrella Durá‐Ferrandis
Estrella Durá‐Ferrandis
JMJeanne S. Mandelblatt
Jeanne S. Mandelblatt
JCJonathan Clapp
Jonathan Clapp
GLGeorge Luta
George Luta
LFLeighAnne Faul
LeighAnne Faul
AHArti Hurria
Arti Hurria

10 June 2015 in International Journal of Tourism Research
Verified
Journal Article
Closed access
PDF file
JFJordi Garcés Ferrer
Jordi Garcés Ferrer
MSMireia Ferri Sanz
Mireia Ferri Sanz
EFEstrella Durá Ferrandis
Estrella Durá Ferrandis
SMScott McCabe
Scott McCabe
Javier SanchezJavier Sanchez
Javier Sanchez

1 December 2008 in Journal of Psychosomatic Research
Verified
Journal Article
Closed access
MGMa José Galdón
Ma José Galdón
EDEstrella Durá
Estrella Durá
YAYolanda Andreu
Yolanda Andreu
MFMaite Ferrando
Maite Ferrando
SMSergio Murgui
Sergio Murgui
EIElena Ibañez
Elena Ibañez

1 August 2004 in Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontology
Verified
Journal Article
Closed access
MFMaite Ferrando
Maite Ferrando
YAYolanda Andreu
Yolanda Andreu
MGM. José Galdón
M. José Galdón
EDEstrella Durá
Estrella Durá
RPRafael Poveda
Rafael Poveda
JBJose Vincente Bagán
Jose Vincente Bagán